Drugs / SR419
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05012761 | Aug → Dec 2021 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04705077 | Feb → Mar 2021 | — | SIMR (Australia) Biotech Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04021563 | Jul → Dec 2019 | — | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04494815 | Sep 2020 → May 2022 | neuropathy, painful | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05357677 | May 2022 → Jan 2023 | postherpetic neuralgia | Shanghai SIMR Biotechnology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SR419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04021563 ↗ |
| Route | Oral | “Ascending single and multiple doses of SR419 orally” NCT04021563 ↗ |